• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

May 26, 2021

Study Links Decrease in Cervical Cancer Incidence to Screening, HPV Vaccination

Author(s):

Kristen Coppock, MA
Conference|ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Other HPV-associated cancers were found to have increased over the study period, linking this trend to lack of guidelines and other resources.

A review of data for more than 650,000 patients with human papillomavirus (HPV)-associated cancers found the incidence of cervical cancer has decreased annually by 1% over a period of 17 years. However, investigators also found certain other types of cancers associated with the HPV had increased significantly during the same period between 2001 and 2017.1-3

The study authors reviewed data from the US Cancer Statistics program, with the results from the study being presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 to 8, 2021.1

The study’s lead author Cheng-I Liao, MD, Kaohsiung Veterans General Hospital, in Kaohsiung, Taiwan, said in an ASCO webcast that HPV is associated with more than 90% cervical and anal cancers, as well as 60 to 75% of oropharyngeal, vulvar, vaginal, and penile cancers. According to investigators, 52% of all HPV-associated cancers were incidence of cervical cancer during the study period.2

“It is likely that the significant decrease in cervical cancer incidence results from clear guidelines for cervical cancer screening and may also reflect promotion and acceptance of [HPV] vaccination, particularly in younger women,” Liao said in a press release.1

The HPV vaccine was first approved in 2006 for girls and young women ages 9 to 26 years as prevention against HPV infection and the development of cervical cancer lesions. Recommendations for HPV vaccination were later extended to boys ages 11 to 12 years, and for everyone up to age 45 years.1

In their study, investigators analyzed cervical cancer incidence in patients aged 20 to 24 years. Compared to older cohorts, women in the 20 to 24 years age group were found to have a disproportionately greater decrease in the incidence of cervical cancer at 4.63% per year, suggesting a potential effect of vaccination, according to the study authors.1

However, although data found that cervical cancer incidence continues to decrease in the United States, the investigators also found increasing incidence of oropharyngeal, anal and rectal, and vulvar squamous cell carcinoma during the same study period at annual percent changes of 0.77%, 2.75%, and 1.27%, respectively. According to the study authors, the increase in cancer types among women is projected to surpass that of cervical cancer by 2025 in every age group over 50 years.3

Additionally, the study found an overall annual increase in HPV-related cancers in men—2.36% annually— with the highest increase in oropharyngeal cancer.3 In fact, 81% of all HPV-related cancers in men were incidences of oropharyngeal cancer, which was approximately 5 times more likely than incidence in women.1,3

According to the study’s investigators, there are no clear guidelines nor standardized screening that exist for certain HPV-related cancers, including oropharyngeal, vulvar, vaginal, penile, anal, and rectal cancers.1

“In order to reduce these trends and achieve success comparable to what we’re seeing with cervical cancer, we must develop effective screening strategies and determine vaccine efficacy in these patient populations,” Liao said in the press release.1

In a prepared statement, ASCO President Lori J. Pierce, MD, FASTRO, FASCO applauded the study’s finding around the decrease in cervical cancer incidence and said it may reflect efforts to increase screenings and vaccinations of patients at risk.1

“Clearly, this study shows that we still have a great deal of work to do in order to reverse the increasing incidence rates of other HPV-related cancers,” Pierce said in the press release.1

According to investigators, they plan to analyze the rates of HPV testing and vaccination from other databases to obtain additional information. They also noted that additional resources and research are still needed to address the lack of disease screening as well as vaccination recommendations for HPV- associated cancers outside of cervical cancer.1,3

REFERENCES

  1. With Strong Screening and Vaccination Guidelines, Cervical Cancer Rates Drop; Other HPV-Related Cancers Are on the Rise [news release]. May 19, 2021; American Society of Clinical Oncology. Accessed May 26, 2021. https://www.asco.org/about-asco/press-center/news-releases/strong-screening-and-vaccination-guidelines-cervical-cancer?cid=DM7637&bid=80018089
  2. HPV Associated cancers in the US over the last 17 years‑Has screening or vaccination made any difference? Presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Presscast. May 14, 2021. Accessed May 26, 2021. https://www.youtube.com/watch?v=KgK0gQJh0tw&t=40s
  3. Liao CI, Caesar MAP, Chan C, et al. HPV-associated cancers in the United States over the last 15 years: Has screening or vaccination made any difference? J Clin Oncol 39, 2021 (suppl 15; abstr 107) doi: 10.1200/JCO.2021.39.15_suppl.107 https://meetinglibrary.asco.org/record/196627/abstract

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Pharmacy Times OPC
Related Content
Advertisement
Hepatocellular Carcinoma Cells: These liver cells, or hepatocytes, can develop into tumors in the liver, often associated with cirrhosis or chronic liver disease - Image credit: Best | stock.adobe.com
July 7th 2025

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Non Small Cell Lung Cancer (NSCLC) in the lung tissue - super closeup view 3d illustration
July 7th 2025

Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Humira (adalimumab), reference product to Hadlima, Hyrimoz -- Image credit: Boris | stock.adobe.com
July 4th 2025

Real-World Data Show Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Gillian McGovern, Associate Editor
HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com
July 2nd 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Hepatocellular Carcinoma Cells: These liver cells, or hepatocytes, can develop into tumors in the liver, often associated with cirrhosis or chronic liver disease - Image credit: Best | stock.adobe.com
July 7th 2025

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Non Small Cell Lung Cancer (NSCLC) in the lung tissue - super closeup view 3d illustration
July 7th 2025

Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Humira (adalimumab), reference product to Hadlima, Hyrimoz -- Image credit: Boris | stock.adobe.com
July 4th 2025

Real-World Data Show Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Gillian McGovern, Associate Editor
HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com
July 2nd 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.